Gérard A. Limoges, C.M., FCPA., FCA., Adm.A.
Gérard Limoges is a Corporate Director since 1999, after a career of 37 years with Ernst & Young Canada. He was in the later years, the Deputy Chairman of the Canadian firm.
He graduated from HEC MONTRÉAL (University of Montréal) in 1966 and became Chartered Accountant after writing the CA exams. (Honors: Governor General’s Gold Medal for the highest marks in Canada and Gold Medal of the Order of CA of Quebec).
Gérard Limoges received the Order of Canada in 2002.
Pierre-Yves Desbiens, CPA, CA, CF, MBA
Pierre-Yves Desbiens is currently Vice-President Finance and Operations of the NEOMED Institute. He has 30 years of professional experience, mostly in the Biotech/Pharmaceutical Industry as a CFO, except for 2 years when he was an Investment Portfolio Manager, Life Sciences, at the Fonds de Solidarité des Travailleurs du Québec (FSTQ). As CFO through the years he raised financing in the private sector with venture capitalists, private individuals and governments. As one of the key players in the creation of the NEOMED Institute, 3 years ago, he help raised $95 M in a mix of contributions from pharmas and governments. He successfully converted 200,000 sqft of research centers (in Ville St-Laurent and Laval) into vibrant ecosystems hosting 28 CROs/Biotechs with more than 300 scientists, 90 of which are working directly for the NEOMED Institute and its subsidiary NEOMED-LABS Inc.
Moneesh Chatterjee, Ph.D.
Moneesh Chatterjee brings over 25 years of experience in the Pharmaceutical and Chemical industries. During this time he demonstrated leadership in Drug Discovery, Innovative Technologies and Business Development. He led multidisciplinary teams in pharmaceutical R&D that included scientific alliances and collaborations with academia. He has authored over 25 manuscripts, patents and presentations.
Dr. Chatterjee’s interests remain at the interface of engineering, chemistry and biology. In the early part of his career he worked in process engineering and the design of chemical factories. He then received a Ph.D. in bioorganic chemistry at Stony Brook University and followed that with a Postdoctoral fellowship at The Johns Hopkins University where he elucidated the mechanism of action of specific anticancer agents. Following his postdoctoral studies, Dr. Chatterjee joined Bristol-Myers Squibb (BMS) in 1995 in the Virology Department where he worked on a number of drug discovery projects in HIV, Hepatitis B and Hepatitis C. He then broadened his experience in drug discovery, holding positions of increasing responsibility in lead discovery, compound management and profiling.
Lastly, he moved to the Strategic Transactions and Business Development Groups at BMS to lead the Global Search, Evaluation and Due Diligence efforts in support of all in-licensing and M&A interests for Virology and Fibrosis. During this time, he implemented an extensive U.S. business development outreach program to the Biotech and Venture Capital community to support long term relationship building with key companies. During his tenure, about 450 opportunities were evaluated with Pharma, Biotech and Academia.
Currently, Dr. Chatterjee is a consultant for Pharma and Biotech, VP of Discovery and Product Development at InanoBio and a Member of the Board of Directors at BPDWID.
Michel Bazinet, M.D.
Michel Bazinet is CEO and Chief Medical Officer of Replicor. He is responsible for the development strategy of the Company, and oversees all operations, including the planning of clinical trials. Previously, Dr. Bazinet worked as assistant professor in the departments of Urology and Oncology at McGill University in Montreal. He did his medical training at Sherbrooke University, his urology training at McGill University after which he did a 3-year fellowship in human tumor immunology and urologic oncology at the Memorial Sloan-Kettering Cancer Center in New York from 1984 to 1987. In 1996 Dr. Bazinet founded Mediconsult, and was the Medical Director when it listed on NASDAQ in 1999. Dr. Bazinet has previously served as a member of the board of directors for 2 public companies and has been a consultant for many biotechnology projects.